Portfolio company news

All Group media enquiries should be directed to
Vanessa Maydon, Corporate Affairs Director.

Cinven Partners LLP
Warwick Court
Paternoster Square
London EC4M 7AG

 

Tel: +44 (0)20 7661 3325
Mob: +44 (0)7802 961 902
Email: Vanessa Maydon

Press releases

Medpace
16 August 2017

Cinven successfully sells down Medpace shares in partial realisation

Cinven today announces that it has successfully completed the sale of two million shares, representing approx. 9% of its stake, in Medpace Holdings Inc (‘Medpace’ or ‘the Group’), the leading global contract research organisation (CRO) at US$30.27 per share, to the company. 

This is the first sale of shares by Cinven following an all-primary IPO on the Nasdaq Global Select Market in August 2016 with the share price representing a 32% increase over the IPO price at US$23 per share. 

Following the offering, Cinven’s remaining stake in Medpace represents around 56% of the Group’s outstanding basic shares.  The transaction is expected to close on or around 22 August 2017, subject to customary closing conditions.